Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: Therapeutic perspectives

Kidney International

Volumn 74, Issue 7, 2008, Pages 873-878

  Ronco, Pierre ^a,b   Chatziantoniou, Christos ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

Author keywords

Discoidin domain receptor 1; Extracellular matrix; Integrin; Matrix metalloproteinases; Transglutaminase

Indexed keywords

CELL RECEPTOR; DISCOIDIN DOMAIN RECEPTOR 1; ENZYME INHIBITOR; GELATINASE; GELATINASE A; GELATINASE B; HYALURONAN RECEPTOR; INTEGRIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE RECEPTOR; NONPEPTIDOMIMETIC INHIBITOR; PEPTIDOMIMETIC INHIBITOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RECEPTOR PROTEIN; STROMELYSIN; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ALPORT SYNDROME; BASEMENT MEMBRANE; DISEASE COURSE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; EXTRACELLULAR MATRIX; HUMAN; KIDNEY DISEASE; NEPHROANGIOSCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCLEROSIS;

EID: 51849139372     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.349     Document Type: Article

References (30)

1. Chatziantoniou C, Dussaule JC. Is kidney injury a reversible process? Curr Opin Nephrol Hypertens 2008; 17: 76-81.
2. Boffa JJ, Lu Y, Placier S et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14: 1132-1144.
3. Ronco P, Lelongt B, Piedagnel R et al. Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin Nephrol 2007; 27: 352-362.
4. Cheng S, Pollock AS, Mahimkar R et al. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006; 20: 1898-1900.
5. Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937-1949.
6. Flamant M, Placier S, Dubroca C et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007; 50: 212-218.
7. Zeisberg M, Khurana M, Rao VH et al. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 2006; 3: e100.
8. Kalluri R, Shield CF, Todd P et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997; 99: 2470-2478.
9. Iwano M, Plieth D, Danoff TM et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350.
10. Yang J, Shultz RW, Mars WM et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002; 110: 1525-1538.
11. Horstrup JH, Gehrmann M, Schneider B et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant 2002; 17: 1005-1013.
12. Lelongt B, Bengatta S, Delauche M et al. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Med 2001; 193: 793-802.
13. Johnson TS, El-Koraie AF, Skill NJ et al. Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 2003; 14: 2052-2062.
14. Skill NJ, Johnson TS, Coutts IG et al. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem 2004; 279: 47754-47762.
15. Johnson TS, Fisher M, Haylor JL et al. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 2007; 18: 3078-3088.
16. Cosgrove D, Rodgers K, Meehan D et al. Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 2000; 157: 1649-1659.
17. Hahm K, Lukashev ME, Luo Y et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007; 170: 110-125.
18. Henger A, Kretzler M, Doran P et al. Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int 2004; 65: 904-917.
19. Chen X, Moeckel G, Morrow JD et al. Lack of integrin alpha1beta1 leads to severe glomerulosclerosis after glomerular injury. Am J Pathol 2004; 165: 617-630.
20. Chen X, Abair TD, Ibanez MR et al. Integrin alpha1beta1 controls reactive oxygen species synthesis by negatively regulating epidermal growth factor receptor-mediated Rac activation. Mol Cell Biol 2007; 27: 3313-3326.
21. Li Y, Dai C, Wu C et al. PINCH-1 promotes tubular epithelial-tomesenchymal transition by interacting with integrin-linked kinase. J Am Soc Nephrol 2007; 18: 2534-2543.
22. Hu K, Wu C, Mars WM et al. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J Clin Invest 2007; 117: 3821-3832.
23. Verkoelen CF, Verhulst A. Proposed mechanisms in renal tubular crystal retention. Kidney Int 2007; 72: 13-18.
24. Wu H, Chen G, Wyburn KR et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117: 2847-2859.
25. Rouschop KMA, Claessen N, Pals ST et al. CD44 disruption prevents degeneration of the capillary network in obstructive nephropathy via reduction of TGF-beta1-induced apoptosis. J Am Soc Nephrol 2006; 17: 746-753.
26. Lewis A, Steadman R, Manley P et al. Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis. Histol Histopathol 2008; 23: 731-739.
27. Vogel W, Gish GD, Alves F et al. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1997; 1: 13-23.
28. Matsuyama W, Kamohara H, Galligan C et al. Interaction of discoidin domain receptor 1 isoform b (DDR1b) with collagen activates p38 mitogen-activated protein kinase and promotes differentiation of macrophages. FASEB J 2003; 17: 1286-1288.
29. Flamant M, Placier S, Rodenas A et al. Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J Am Soc Nephrol 2006; 17: 3374-3381.
30. Lutz J, Yao Y, Song E et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 2005; 79: 655-661.